We are backed by a team of pioneering
longevity researchers

The Best Minds in Longevity Science

Highest Credentials

Our scientific advisors are biochemists, geneticists and professors from Harvard, MIT, University of Liverpool, University of Washington, and other universities around the world.

Awards + Honors

Our scientists have received honors that include Breakthroughs in Gerontology Award, an Alzheimer’s Association New Investigator Award, and an Ellison Medical Foundation New Scholar in Aging Award.


Each one of them is a pioneer in the longevity field and have been featured by 60 Minutes, TIME magazine, BBC, CNN, Science, Scientific American, Washington Post, New York Times, and countless other publications.

Meet our Scientific Advisory Board

Dr. George Church, PhD

Harvard Medical School & MIT Professor

Dr. George Church published the first direct genomic sequencing method in 1984 and is known as the father of synthetic biology and personalized genomics. Dr. Church has received various accolades, which include election to the National Academy of Sciences and the National Academy of Engineering. He is a recipient of the American Society for Microbiology Promega Biotechnology Research Award. His most cited work has been published in peer reviewed scientific journals including PNAS, Nature Genetics, Nature Biotechnology, Science, the Journal of Molecular Biology, Nature, and many others.

Dr. Pamela Maher, PhD

University of British Columbia, Salk Institute for Biological Studies

Dr. Maher worked for 5 years as an assistant professor at the Whittier Institute for Diabetes and Endocrinology in La Jolla, CA, then moved to The Scripps Research Institute in 1994 as an associate professor. In 2004, she moved to her current position at The Salk Institute. Her research interests focus on using natural products such as flavonoids, small molecules that are widely distributed in fruits and vegetables, to maintain nerve cell function in the presence of toxic insults, especially in relation to Alzheimer’s, dementia & Parkinson’s.

Dr. J Pedro de Magalhaes, PhD

Harvard Medical School, University of Liverpool

Dr. de Magalhaes leads the Integrative Genomics of Aging Group at the Institute of Integrative Biology, University of Liverpool, UK. Dr. de Magalhaes completed his postdoc with genomics pioneer, Dr. George Church, at Harvard Medical School. He developed high throughput approaches for studying aging, including computational tools and databases, statistical models of mortality, and comparative genomics methods for investigating the evolution of longevity. Dr. de Magalhaes maintains several databases related to the impact that drugs & natural substances have on aging.

Dr. Matt Kaeberlein, PhD

Harvard Medical School & MIT Professor

Professor of Pathology, Adjunct Professor of Genome Sciences, and Adjunct Professor of Oral Health Sciences at the University of Washington. Dr. Kaeberlein’s research interests focus on basic mechanisms of aging in order to identify interventions that promote healthspan and improve quality of life. He has published nearly 200 papers in top scientific journals and has been recognized by prestigious awards, including Breakthroughs in Gerontology, Alzheimer’s Association Young Investigator Award, Ellison Medical Foundation New Scholar in Aging, a Murdock Trust Award, Pioneer in Aging, and Vincent Cristofalo Rising Star in Aging Research.

Dr. Oliver Medvedik, PhD

Harvard Medical School, The Cooper Union

Director of the Kanbar Center for Biomedical Engineering, Cooper Union. Dr. Medvedik has worked as a biotechnology consultant at Sirtris Pharmaceuticals and has taught molecular and synthetic biology to hundreds of students while at Harvard University, The Cooper Union, School of Visual Arts, Genspace and NYU. He is also co founder and vice president of the non profit organization LEAF (Life Extension Advocacy Foundation), where he serves on the board of directors. LEAF has launched a crowd funding platform for fiscally sponsoring research directed towards longevity and diseases of aging.

Dr. Avi Rosenbaum, PhD

Harvard Medical School

Scientist and Consultant, with deep knowledge of the biotech industry. Experience and international network in Genomics, Personalized Medicine, Gene Therapy and Synthetic Biology. Built the first academic Next Generation Sequencing platform. Launched more than ten commercial products. Investor and mentor in biotech, pharma, medical and food tech companies. Holder of five patents, and co author of high profile academic publications with over 2,500 citations.

Founders with a mission to make the latest scientific advances in longevity accessible and achievable for all.

Chris Mirabile

Founder & CEO

Chris Mirabile, Founder & CEO of NOVOS, is a serial entrepreneur and longevity expert. Chris’ interest in health began when he was 12, and evolved into a passion after he was cured of a brain tumor when he was 16. Chris has researched and integrated longevity practices and interventions into his life for more than ten years, has achieved a biological age 13.6 years younger than his chronological age, and according to epigenetic tests like DunedInPACE, is aging 31% slower biologically than chronologically.

Dr. Kris Verburgh, MD


Kris Verburgh is a medical doctor specialized in aging and longevity. He is a researcher at the University of Brussels and faculty member at Singularity University Benelux where he teaches about the future of medicine and longevity. He is a partner at a $100 million investment fund that invests in new technologies to address aging. He wrote his first science book when he was 16 years old, and by age 28 he had written four science books, including The Longevity Code. Since a young age he has given talks for many organizations and institutions, including European Parliament, Cambridge University, and various Fortune 100 companies.

Our team of pioneering longevity researchers developed Novos’ products through the latest advancements in scientific research

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.